Literature DB >> 30489526

Percutaneous Aponeurotomy and Lipofilling versus Limited Fasciectomy for Dupuytren's Contracture: 5-Year Results from a Randomized Clinical Trial.

Ruud W Selles1, Chao Zhou1, Hester J Kan1, Robbert M Wouters1, Christianne A van Nieuwenhoven1, Steven E R Hovius1.   

Abstract

BACKGROUND: In the Dupuytren Rotterdam randomized controlled trial, percutaneous aponeurotomy with lipofilling (PALF) was as effective as limited fasciectomy in correcting primary Dupuytren's contracture after 1 year. The authors report the 5-year results of this trial, with a special focus on recurrence of contractures.
METHODS: The authors invited all patients who had undergone PALF or limited fasciectomy to participate in a posttrial follow-up assessment. Thirty-one PALF patients and 21 limited fasciectomy patients were assessed by an independent examiner for the degree of contracture and whether patients had undergone a secondary procedure. The primary composite endpoint was recurrence rate, defined as either 20 degrees or greater worsening in contracture (relative to week 3) or as having undergone a secondary procedure for a new or worsening contracture.
RESULTS: At 5 years, more joints in the PALF group than in the limited fasciectomy group had a recurrence (74 percent versus 39 percent; p = 0.002). When redefining recurrence as a worsening in total extension deficit of at least 30 degrees for treated digits as often reported, this was 77 percent versus 32 percent (p = 0.001). Total extension deficit was also worse for PALF-reated digits (53 degrees versus 31 degrees; p < 0.010).
CONCLUSIONS: Although the authors previously reported that PALF offers a shorter convalescence and fewer long-term complications but a similar degree of contracture correction at 1-year follow-up, at 5 years, the corrections were less durable than those for limited fasciectomy. This again highlights that limited fasciectomy and different types of needle aponeurotomy have specific advantages and disadvantages to weigh by patients and clinicians. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

Entities:  

Mesh:

Year:  2018        PMID: 30489526     DOI: 10.1097/PRS.0000000000004982

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  8 in total

Review 1.  Fat Grafting for Hand Rejuvenation.

Authors:  Christopher J Conlon; Amjed Abu-Ghname; Matthew J Davis; Kausar Ali; Sebastian J Winocour; Michael L Eisemann; Julian Winocour
Journal:  Semin Plast Surg       Date:  2020-02-15       Impact factor: 2.314

2.  Percutaneous Needle Fasciotomy versus Collagenase Injection for Dupuytren's Contracture: A Systematic Review of Comparative Studies.

Authors:  Takashi Hirase; Rishi Suresh; Michael O Cotton; Alex Han; Matthew B Burn; Joshua D Harris; Shari R Liberman
Journal:  J Hand Microsurg       Date:  2020-12-31

Review 3.  Dupuytren's Disease: An Outcomes-Focused Update.

Authors:  Yasser H Almadani; Joshua Vorstenbosch; Johnny Ionut Efanov; Liqin Xu
Journal:  Semin Plast Surg       Date:  2021-07-06       Impact factor: 2.195

4.  Cost-effectiveness of Recurrent Dupuytren Contracture Treatment.

Authors:  Alfred P Yoon; Robert L Kane; David W Hutton; Kevin C Chung
Journal:  JAMA Netw Open       Date:  2020-10-01

5.  Versatility of percutaneous needle fasciotomy for Dupuytren's disease across a spectrum of disease severity: A single-surgeon experience of 118 rays.

Authors:  Manal I A Patel; Irshad A Patel
Journal:  JPRAS Open       Date:  2020-11-30

6.  Fibroproliferative disorders and diabetes: Understanding the pathophysiologic relationship between Peyronie's disease, Dupuytren disease and diabetes.

Authors:  Martin K Gelbard; Joel Rosenbloom
Journal:  Endocrinol Diabetes Metab       Date:  2020-10-31

Review 7.  Treatment Options for Dupuytren's Disease: Tips and Tricks.

Authors:  Keith A Denkler; Keon Min Park; Osaid Alser
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-01-27

8.  Serious complications and risk of re-operation after Dupuytren's disease surgery: a population-based cohort study of 121,488 patients in England.

Authors:  Osaid Alser; Richard S Craig; Jennifer C E Lane; Albert Prats-Uribe; Danielle E Robinson; Jonathan L Rees; Daniel Prieto-Alhambra; Dominic Furniss
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.